论文部分内容阅读
目的总结评价冠心病合并心律失常患者的临床治疗药物的安全性和疗效。方法选择入院后诊断为冠心病合并心律失常的患者80例,随机分为稳心颗粒组(治疗组)和胺碘酮组(对照组),用药时间1个月,观察治疗药物稳心颗粒对冠心病合并心律失常患者的临床疗效和不良反应。结果两组药物对冠心病合并心律失常治疗前后比较无统计学差异(P>0.05)。而且两组药物均能使患者期前收缩次数明显减少(P>0.01)。结论稳心颗粒治疗冠心病合并心律失常患者的疗效与胺碘酮相当,但是临床不良反应的发生比率明显低于胺碘酮,适合治疗各类心律失常。
Objective To summarize the safety and efficacy of clinical treatment of patients with coronary heart disease complicated with arrhythmia. Methods 80 patients diagnosed as coronary heart disease with arrhythmia after admission were randomly divided into Wenxin Granule group (treatment group) and amiodarone group (control group) for one month. The effect of Wenxin Granule Clinical efficacy and adverse reactions in patients with coronary heart disease and arrhythmia. Results There was no significant difference between the two groups before and after treatment of coronary heart disease and arrhythmia (P> 0.05). And the two groups of drugs can make patients significantly reduce the number of premature contractions (P> 0.01). Conclusion Wenxin Granule is equivalent to amiodarone in patients with coronary heart disease and arrhythmia, but the incidence of clinical adverse reactions is significantly lower than that of amiodarone, which is suitable for the treatment of various arrhythmias.